In another phase 1 clinical trial involving advanced gastrointestinal tumors, including HCC, patients treated with anti-PD-1 antibodies were categorized into four groups based on the baseline PD-L1 expression level in CTCs: negative, low, medium, and high. Here, CD274 is linked to digestive system neoplasm.